Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

John Winikates

Neurology Columbus, IN Medical Doctor

NPI 1386697712 CMS profile 153104

2138 25Th St Ste F, Columbus, IN 47201

Open in the dashboard

General payments

$1,760

149 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John Winikates of Columbus, IN is reported in the CMS Open Payments database as having received $1,760 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $17 1
2020 General $245 16
2019 General $1,498 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Winikates
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to John Winikates were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year John Winikates Neurology median Middle half National median
2019 $1,498 $474 $118–$2,177 $163
2020 $245 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $17 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Supernus Pharmaceuticals, Inc. $318 30 payments
  2. UCB, Inc. $194 26 payments
  3. EMD Serono, Inc. $185 22 payments
  4. Biogen, Inc. $143 9 payments
  5. Genzyme Corporation $134 8 payments
  6. Eisai Inc. $126 6 payments
  7. Novartis Pharmaceuticals Corporation $123 11 payments
  8. AbbVie, Inc. $54 3 payments
  9. Pfizer Inc. $39 3 payments
  10. Genentech USA, Inc. $39 3 payments
  11. Other $406 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,760 149 payments
Products named General payments · program years 2019–2022
  1. OXTELLAR XR $318 30 payments
  2. Briviact $162 22 payments
  3. Mavenclad $135 14 payments
  4. TYSABRI $131 8 payments
  5. TECFIDERA $131 8 payments
  6. Fycompa $126 6 payments
  7. AUBAGIO $117 7 payments
  8. AIMOVIG $69 6 payments
  9. PLEGRIDY $55 3 payments
  10. DUOPA $54 3 payments
  11. Other $738 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$8,968

Medicare's payments for the services billed

Medicare patients

116

Average age 72

Services billed

160

69 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 40%
Depression 37%
Ischemic heart disease 34%
Chronic kidney disease 25%
COPD 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record